Avila Therapeutics, 100 Beaver Street, Waltham, Massachusetts 02453, USA.
Nat Rev Drug Discov. 2011 Apr;10(4):307-17. doi: 10.1038/nrd3410.
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
共价药物已被证明是治疗各种适应症的有效疗法,但在启动靶向药物发现项目时,由于安全性问题,它们很少被考虑。有必要重新评估这一重要类别的药物,并调和共价药物的历史成功与大多数药物发现团队不愿将其纳入其武器库之间的不和谐。本文综述了共价药物的普遍性和药理学优势,讨论了如何通过创新设计来解决潜在的风险和挑战,并介绍了靶向共价抑制剂带来的广泛机会。